S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
The Small Biotech Scaring Big Pharma (Ad)
Ukraine urges tougher Western squeeze on Russian oil prices
UK arrests wealthy Russian as police target Putin enablers
Why Your IRA Could Crash on January 16th? (Ad)
Moldova signs new energy deal that could ease blackout risk
Tennessee roads plan mulls toll lanes, electric car fee hike
ETR:MDG1

Medigene - MDG1 Stock Forecast, Price & News

€2.24
-0.04 (-1.75%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
€2.22
€2.27
50-Day Range
€1.89
€2.42
52-Week Range
€1.75
€4.59
Volume
2,013 shs
Average Volume
306,207 shs
Market Capitalization
$55.02 million
P/E Ratio
5.74
Dividend Yield
N/A
Price Target
N/A
MDG1 stock logo

About Medigene (ETR:MDG1) Stock

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

MDG1 Stock News Headlines

Medigene Announces Strategy and Corporate Update
Medigene AG (MDG1.DE)
PTA-News: Medigene AG: Veränderung im Vorstand
MEDIGENE AG MEDIGENE K ORD SHS (0QGJ.IL)
PHIO: Intasyl Advantage vs. Gene Editing
MEDIGENE AG NA O.N. (MDG1.DU)
MediGene AG
Medigene H1 Net Loss Widens; Backs FY19 Outlook - Quick Facts
PHIO: Activation in the Tumor Microenvironment
See More Headlines
Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
58
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$31.46 million
Cash Flow
€1.55 per share
Book Value
€2.41 per share

Miscellaneous

Free Float
N/A
Market Cap
$55.02 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Dolores J. Schendel
    Chief Scientific Officer, Member of Exec. Management Board and Head of R&D
  • Dr. Selwyn Ho MB BS (Age 51)
    MBBS, CEO & Member of Exec. Management Board
  • Dr. Ernst-Ludwig Winnacker (Age 81)
    Co-Founder & Chairman Scientific Advisory Board
  • Dr. Birger Kohlert
    Chief Financial Officer
  • Dr. Anna Niedl
    VP Investor Relations & Corp. Communications
  • Dr. Rene Goedkoop
    Acting Chief Medical Officer













MDG1 Stock - Frequently Asked Questions

How have MDG1 shares performed in 2022?

Medigene's stock was trading at €2.87 at the beginning of 2022. Since then, MDG1 shares have decreased by 21.8% and is now trading at €2.24.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of Medigene own?
What is Medigene's stock symbol?

Medigene trades on the ETR under the ticker symbol "MDG1."

What is Medigene's stock price today?

One share of MDG1 stock can currently be purchased for approximately €2.24.

How much money does Medigene make?

Medigene (ETR:MDG1) has a market capitalization of $55.02 million and generates $31.46 million in revenue each year.

How can I contact Medigene?

Medigene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The official website for the company is www.medigene.de. The company can be reached via phone at +49-89-2000330.

This page (ETR:MDG1) was last updated on 12/4/2022 by MarketBeat.com Staff